Catalyst Event
Alteogen Inc (196170) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
3/19/2026, 12:00:00 AM
The second-largest shareholder's opposition to the CFO's re-appointment on March 19, 2026, is expected to cause a >1% price impact due to governance concerns, scheduled.
Korean Translation
2026년 3월 19일로 예정된 2대 주주의 CFO 사내이사 재선임 반대 의사 표명은 지배구조 우려로 인한 1% 이상의 주가 변동이 예상됨.
Related Recent Events
Hanmi Pharm Co Ltd (128940) · Other
Annual general shareholder meeting on 2026-03-31 to vote on the appointment of a new CEO and board members amid a management dispute; high impact estimated due to potential governance shift scheduled.
3/31/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Other
The 20th Annual General Shareholders' Meeting on March 31, 2026, to approve financial statements and appoint a new director (Low importance estimated as standard annual meetings without major corporate changes usually have minimal price impact) scheduled
3/31/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
The 25th Annual General Meeting of Shareholders is scheduled for March 26, 2026. Low importance is estimated as the agenda items are routine and unlikely to cause significant price volatility scheduled.
3/26/2026, 12:00:00 AM
Chong Kun Dang Pharm Co (185750) · Other
The 13th Annual General Meeting of Shareholders is scheduled.
3/26/2026, 12:00:00 AM
Alteogen Inc (196170) · Other
Alteogen's exclusive license agreement with Biogen for its ALT-B4 technology on March 25, 2026, is expected to have a >10% price impact due to the significant deal size of 867.6 billion KRW, scheduled.
3/25/2026, 12:00:00 AM
AprilBio Co Ltd (397030) · Other
The 13th Annual General Meeting of Shareholders was held on March 25, 2026. Resolutions passed included the approval of the 2025 financial statements, amendments to the articles of incorporation, and the granting of stock options.
3/25/2026, 12:00:00 AM